State of Wyoming’s Prelude Therapeutics PRLD Stock Holding History

State of Wyoming’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-544	Closed	-$7K	–	1980
2021 Q4	$7K	Sell	544 -29	-5%	-$472	﹤0.01%	1699
2021 Q3	$18K	Sell	573 -276	-33%	-$8.94K	0.01%	956
2021 Q2	$24K	Buy	849 +450	+113%	+$16K	0.02%	894
2021 Q1	$17K	Buy	+399	New	+$26.5K	0.03%	338

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State of Wyoming's PRLD Position: Q1 2022 in Review

State of Wyoming sold out of Prelude Therapeutics (PRLD) in Q1 2022, closing a stake of 544 shares — an estimated $7K sold.

State of Wyoming first reported a position in PRLD in Q1 2021 and held it in 4 quarters. The position peaked at $24K in Q2 2021. 68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

State of Wyoming reported no remaining Prelude Therapeutics position as of Q1 2022 after selling out during the quarter.
State of Wyoming sold 544 Prelude Therapeutics shares in Q1 2022, an estimated $7K.
State of Wyoming first reported a position in Prelude Therapeutics in Q1 2021 and held it in 4 quarters.
State of Wyoming's Prelude Therapeutics position peaked at $24K in Q2 2021.
68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on State of Wyoming's 13F filing for Q1 2022, filed 13 May 2022.